The U.S. Food and Drug Administration (FDA) has sparked significant discussion among oncology stakeholders following the release of its draft guidance on dose optimization for radiopharmaceutical therapies (RPTs). Issued in August 2025, the document aims to help sponsors determine safe and effective dosing strategies for radioactive drugs used in cancer treatment. While the agency’s focus on safety has been broadly welcomed, industry leaders and research organizations are urging the FDA to allow greater flexibility to ensure that patient access and innovation are not hindered.
A New Framework for Radiopharmaceutical Dosing
Radiopharmaceutical therapies deliver targeted radiation to cancer cells through a radioactive drug rather than external beams. Because of their unique mechanisms, RPTs present challenges in balancing efficacy and toxicity—particularly as cumulative radiation exposure varies across treatment cycles.
The FDA’s draft guidance attempts to bridge the gap between traditional external beam radiation therapy (EBRT) and RPTs, offering tailored recommendations for determining optimal dosing. However, sponsors and scientific organizations have raised questions about whether the FDA’s current framework is too conservative and whether it aligns with evolving global standards.
Stakeholders Call for Clarity and Flexibility
Friends of Cancer Research (FoCR) voiced broad support for the guidance but asked the FDA to clarify how cumulative dose limits and organ-specific thresholds should be applied to RPTs. The organization noted that EBRT-derived dose limits may not directly translate to radiopharmaceuticals due to differences in radiation distribution, biological effects, and retention times.
FoCR also recommended that the FDA encourage sponsors to incorporate early biomarkers and longitudinal data into clinical designs to detect delayed toxicities more consistently. It urged regulators to provide clearer expectations for adaptive trial designs that use early biomarkers as exploratory safety endpoints in early-phase studies.
Similarly, the European Federation of Organizations for Medical Physics (EFOMP) emphasized the importance of harmonization between U.S. and European regulatory approaches. The group cautioned that terms like “dose” and “dosing” can vary in meaning across medical disciplines and encouraged the FDA to refine its terminology and align its framework with international directives.
Industry Feedback Highlights Balance Between Risk and Benefit
Pharmaceutical companies including Eli Lilly and AstraZeneca supported the FDA’s willingness to consider dose escalation beyond traditional EBRT limits when justified by data. Lilly noted that adherence to EBRT thresholds has historically restricted exploration of maximum tolerated doses (MTDs) for RPTs, limiting understanding of their full therapeutic potential.
Both companies, however, cautioned against placing excessive emphasis on cumulative toxicity. AstraZeneca proposed that clinical data—rather than dosimetry alone—should guide dose optimization decisions and called for more flexibility in trial design. The company argued that clinical benefit and patient survival should remain the central focus, even when potential toxicities exist.
A Path Toward Global Harmonization
Across stakeholder comments, one theme is clear: while safety remains paramount, the path forward must allow innovation to flourish. Balancing the need for patient protection with the potential for therapeutic breakthroughs will require close collaboration between regulators, researchers, and industry.
The FDA’s draft guidance marks a step toward standardization in a rapidly evolving field. However, achieving meaningful progress will depend on continued dialogue and alignment with international frameworks such as those from the International Council for Harmonisation (ICH).
The EMMA International Perspective
At EMMA International, we recognize that regulatory clarity and scientific flexibility must coexist for innovation to thrive. As precision medicine and targeted radiotherapies evolve, developers must integrate robust data, modeling, and risk management into their submission strategies. Our team helps organizations navigate FDA guidance development, ensuring that scientific advances align with global standards for safety, efficacy, and compliance.
For more information on how EMMA International can assist, visit www.emmainternational.com or contact us at (248) 987-4497 or info@emmainternational.com.
Reference:
Al-Faruque, F. (2025, October 24). Drugmakers seek greater leeway in radiopharmaceutical dosing guidance. Regulatory Affairs Professionals Society.
U.S. Food and Drug Administration. (2025). Optimizing dosimetry for radiopharmaceutical therapies: Draft guidance for industry. https://www.fda.gov
